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Background/aim: The aims of the present study were to assess the relationship between the distance walked during the 6-min walk
test (6MWT) and exercise capacity as determined by cardiopulmonary exercise testing (CPET) in patients with pulmonary arterial
hypertension (PAH) and to investigate the prognostic value of the 6MWT in comparison to clinical parameters of CPET and
echocardiography findings.
Materials and methods: Thirty PAH patients participated in the study. Subject characteristics and New York Heart Association (NYHA)
classifications were recorded. All subjects completed the 6MWT and CPET. Relationships among the variables were analyzed by the
Pearson correlation test. Correlation coefficients between 6MWT distance and other variables were determined by linear regression
analysis.
Results: Distance walked in the 6MWT was significantly correlated with the following exercise parameters: peak oxygen consumption,
work load, and metabolic equivalents. Additionally, cardiac index was correlated with peak oxygen consumption and metabolic
equivalents. We also showed that cardiac index and age were two significant determinants for exercise performance, accounting for
35.4% of the variance in the 6MWT.
Conclusion: The 6MWT provides information that may be a better index for the patient’s NYHA functional class determination than
maximal exercise testing.
Key words: Six-minute walk test, cardiopulmonary exercise testing, pulmonary arterial hypertension, cardiac index

1. Introduction
Pulmonary arterial hypertension (PAH) is clinically
defined as a mean pulmonary arterial pressure (PAP) of ≥25
mmHg at rest with a normal pulmonary capillary wedge
pressure (PCWP) (1–4). The pathophysiology of PAH
is characterized by progressively increasing pulmonary
vascular resistance (PVR) and right ventricular heart
failure in terms of insufficient oxygen supply of the right
ventricle, which causes limitations in the performance of
daily life activities and exercise intolerance with dyspnea
and fatigue symptoms (4,5).
The New York Heart Association (NYHA) classification
reflects disease severity and prognosis associated with
worsening symptoms during ordinary physical activity and
functional capacity in patients with PAH (6). Additionally,
one of the most feasible methods for noninvasively grading
the severity of exercise limitation and assessing disease
symptoms in PAH is the evaluation of resting and exercise
* Correspondence: serapftr@hotmail.com
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haemodynamics by both submaximal and maximal
exercise test measurements (7–10). Cardiopulmonary
exercise testing (CPET) for the evaluation of disease
severity is important to assess peak oxygen consumption
(VO2peak), metabolic equivalents, and maximal workload
during exercise tests, as well as the minute ventilationto-carbon dioxide output (VE-VCO2) slope (7,8). Paolillo
et al. demonstrated a reduction in VO2peak and remarked
on the prognostic value of the elevated VE-VCO2 slope in
patients with PAH (4). The VE-VCO2 slope reflects disease
severity, and it has been shown that there is a correlation
between the VE-VCO2 slope and NYHA functional class (9).
However, the 6-min walk test (6MWT) is commonly used
in PAH patients as a submaximal exercise test to indicate
the exercise capacity of patients who cannot tolerate the
maximal incremental test, despite the fact that CPET has
more clinical significance in terms of prognostic value and
evaluation of disease severity (11,12). Although the distance
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walked in the 6MWT is significantly shorter among PAH
patients than in age- and sex-matched healthy control
subjects, it does not evaluate the resting hemodynamics,
the response of the cardiopulmonary system, or the
functional gas exchange (7,13). Furthermore, there are no
studies in the literature that demonstrate the prognostic
value of the 6MWT for the NYHA classification in PAH
patients.
Limited data exist concerning the relation between
the 6MWT and incremental CPET in patients with PAH.
Thus, the aims of the present study were to assess the
relation between the distance walked during the 6MWT
and exercise capacity as determined by CPET in patients
with PAH and to investigate the prognostic value of the
6MWT in comparison with the clinical parameters of
CPET and echocardiography findings.
2. Materials and methods
2.1. Study subjects
This study included 30 patients with PAH (including
chronic thromboembolic pulmonary hypertension,
CTEPH) who were followed regularly in the pulmonary
arterial hypertension outpatient clinic of our cardiology
department. Among the patients, 5 (16.7%) had
connective tissue disease, 10 (33.3%) had congenital
heart disease, 2 (6.7%) had CTEPH, and 13 (43.3%) had
idiopathic pulmonary arterial hypertension. One patient
was classified as class I, 19 patients were in class II, and 10
patients were in class III according to the NYHA functional
classification. All patients were treated with PAH-specific
drugs, including bosentan, inhaled iloprost, sildenafil, or a
combination of these drugs, in addition to other palliative
treatments, such as furosemide, spironolactone, and
digoxin, as needed. The diagnosis of PAH was based on
right heart catheterization, with mean PAP >25 mmHg,
PCWP <15 mmHg, and PVR >3 resistance units as
defined by PAH guidelines (10). Patients with severe heart
failure, restrictive and obstructive pulmonary disease, and
acute infection were excluded from the study. All patients
completed the 6MWT and cardiopulmonary exercise
testing when they were clinically stable during outpatient
visits. The Dokuz Eylül University Medical Ethics
Committee approved the study, and all patients provided
written informed consent.
2.2. Measurements
Subject characteristics, including age, height, body
weight, and NYHA classification with PAH etiology,
were recorded. The patients’ dyspnea status was evaluated
using the four-item Modified Medical Research Council
(MMRC) Dyspnea Scale (14). Body mass index (BMI) was
calculated as weight/height squared (expressed in kg/m2).

2.3. Right heart catheterization
A diagnostic right heart catheterization to assess
pulmonary and cardiac haemodynamics was performed
in all patients while they were in a stable condition
during hospitalization. Baseline hemodynamic variables
and mean PAP were measured in all patients. Cardiac
output (CO) was measured by Fick’s method (15). Total
pulmonary resistance was calculated by dividing mean
PAP by CO. Cardiac index (CI) was calculated by dividing
CO by body surface area.
2.4. Six-minute walk test (6MWT)
The 6MWT was conducted for all patients according to
a standardized protocol as described in the American
Thoracic Society (ATS) guidelines (16). Patients were
instructed to walk along a 30-m corridor to cover as much
ground as possible in 6 min. They were encouraged with
standardized statements. The distance covered during
the test, as well as dyspnea and fatigue symptoms, were
evaluated.
2.5. Cardiopulmonary exercise testing (CPET)
All patients performed incremental cardiorespiratory
exercise testing on a cycle ergometer. Gas exchange
measurements (Oxycon Pro) were taken during the
following events: 3 min of rest; 3 min of unloaded leg
cycling for a warm-up followed by 3 min of progressively
increasing the work rate up to 20 W; and 3 min of 20-W
incremental work load. After that, work load was increased
by 3 W every 12 s to maximum tolerance, and gas exchange
measurements were recorded until maximal exertion.
Pulse oximetry (SpO2), heart rate (HR), 12-lead ECG, and
blood pressure were monitored and recorded. Maximal
work load and metabolic equivalent were recorded during
the test. Ventilatory parameters (minute ventilation
(VE), O2 uptake (VO2), and CO2 output (VCO2)) were
interpreted by breath measurement at 6-s intervals. The
anaerobic threshold (AT) percentage of O2 uptake was
calculated and minute ventilation-to-CO2 output at AT
was expressed as VE-VCO2@AT.
2.6. Statistical analysis
Statistical analysis was performed using the SPSS 15.0
(SPSS Inc., Chicago, IL, USA). Analyses included frequency
distribution, percentages, and calculation of means and
related standard deviations (mean ± SD). Continuous
variables, such as summary of demographics, resting
hemodynamics, and CPET, were expressed as means and
standard deviations. Frequency distributions of categorical
variables and continuous variables were included as
descriptive statistics. Relations between 6MWT distance
and catheterization data and 6MWT distance and CPET
data were analyzed for the 30 patients using the Pearson
correlation test. Correlation coefficients between 6MWT
distance and other variables were determined by linear
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regression analysis. The independent contributors to
6MWT that were entered into the analysis were CI and age
variables. Differences between the two functional classes
were analyzed by the Mann–Whitney U test.
3. Results
Most of the 30 PAH patients were middle-aged women
(Table 1) in NYHA class II or III. Their dyspnea symptoms
were mild (54.8%), moderate (22.6%), or severe (6.5%)
according to the MMRC Dyspnea Scale.
At cardiac catheterization, all patients had increased
resting pulmonary hypertension (mean PAP 82.58 ± 21.49
mmHg), increased PVR, and reduced CI (Table 1).
All patients completed the 6MWT and CPET without
incident. The duration of exercise testing in all patients
averaged 9.4 (range: 3 to 15) min. The parameters of
exercise gas exchange were systematically different in
PAH patients. Average peak VO2 was 12.78 ± 4.72 mL kg–1
min–1 with a peak respiratory exchange ratio of 0.97 ± 0.11,
suggesting that the majority of subjects exercised close to
their maximal capacity. There was a marked decrease in
peak oxygen consumption and peak heart rate and an
increase in minute ventilation-to-carbon dioxide output.
The mean distance covered during the 6MWT was 404.75
± 104.07 m (Table 1).
3.1. Correlations
Table 2 summarizes multiple correlations between
the 6MWT and other variables. Age was significantly
negatively correlated with 6MWT distance. The exercise
parameters of peak VO2, peak workload, and metabolic
equivalents (METs) were strongly correlated with 6MWT.
Additionally, CI was correlated with peak VO2 and MET.
Linear regression analysis revealed that age and CI were
significant and independent predictors of performance in
the 6MWT. These two variables accounted for 35.4% of the
variance in the distance covered during the 6MWT (Table
3). The distance covered during the 6MWT was predicted
by the following equation:
Distance (m) = 455.229 + (0.382 × cardiac index) –
(0.494 × age).
3.2. Physiological severity of PAH
Table 4 displays the results of the NYHA gradations
according to the severity of reduction in aerobic capacity.
Moderate PAH patients had an end-exercise respiratory
exchange ratio of 0.95 ± 0.98; severe PAH patients had
a higher end-exercise respiratory exchange ratio (1.00 ±
0.12) compared with moderate PAH patients, indicating
that the patients with PAH had developed significant
metabolic acidosis and had exercised heavily. Using this
method of grading disease severity, there was a statistically
significant difference between the two groups in key
parameters of aerobic function (peak VO2 and MET)
and distance walked in the 6MWT. The average distance
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covered was equivalent for subjects with moderate and
severe PAH (426.05 ± 95.40 m versus 356.75 ± 89.94 m,
respectively; P < 0.05) (Table 4). Furthermore, pulmonary
hemodynamic data regarding mean PAP and PVR were
not statistically significantly different between the two
groups.
4. Discussion
In the present study, we found that 6MWT distance
is severely affected in patients with PAH, and we also
showed that CI and age were two significant determinants
for exercise performance in terms of walking distance.
These two factors accounted for 35.4% of the variance in
the test. Furthermore, the distance walked in the 6MWT
was significantly correlated with the following exercise
parameters: peak VO2, workload, and MET. Additionally,
CI was correlated with peak VO2 and MET. Although there
was an increase in the VE-VCO2 slope in PAH patients,
there was no correlation between the other variables as a
ventilatory response to the exercise test. The data between
the two different NYHA classifications showed that 6MWT
distance and VO2peak statistically significantly decreased in
proportion to the severity of NYHA functional class in
patients with PAH.
We assessed functional exercise capacity using the
6MWT, which primarily evaluates pulmonary and
cardiac impairments in patients with PAH. The self-paced
6MWT evaluates the global and integrated responses of
all the systems involved during exercise (16–18). It has
been shown that the 6MWT test has prognostic value
in disease severity and mortality by revealing decreased
distance in patients with heart failure (19). Additionally,
it was previously shown by Miyamoto et al. that a 6MWT
distance below 332 m is an indicator of poor prognosis
in PAH (7). The moderate and severe PAH patients in
our study demonstrated 6MWT distances of 426.05 and
356.75 m, respectively; these distances were greater than
expected according to their disease severity compared to
the cut-off point of 332 m reported by Miyamoto et al.
for poor prognosis in functional class II and III patients.
Nearly all of the patients in our study walked farther than
in that study (404.75 m).
Linear regression analysis in this study showed that a
large portion of the variance in the 6MWT distance of the
PAH patients was explained by age and CI. This finding
revealed that higher age and lower CI values resulted in
lower functional capacity in patients with PAH. In the
literature, there is only one study, by Britto et al. (20),
reporting that the distance covered during the 6MWT is
significantly associated with age and heart rate variability;
in another study, Miyamoto et al. found that 6MWT
distance is correlated with CO (6). However, there are no
data concerning the relation between 6MWT distance and
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Table 1. Summary of demographics, resting hemodynamics, 6MWT, and CPET
in 30 PAH patients.
Mean ± SD
(n = 30)
Demographics
Age, years

51.93 ± 17.39

Sex, %
Female
Male

77.4
22.6

Height, cm

163.29 ± 10.12

Weight, kg

69.80 ± 15.01

Body mass index, kg/m

24.46 ± 8.10

NYHA class

2.3 ± 0.4

Dyspnea, %
Mild
Moderate
Severe

54.8
22.6
6.5

2

Resting hemodynamics
Systolic pulmonary arterial pressure, mmHg

76.09 ± 25.66

CI, L min–1 m–2

3.13 ± 1.17

Pulmonary vascular resistance, mmHg L min

6.29 ± 2.84

Walk test distance, m

404.75 ± 104.07

–1

–1

CPET
RER maximal work load
Ratio

0.97 ± 0.11

Peak VO2
mL kg–1 min–1

12.78 ± 4.72

Peak work rate
W

132.13 ± 69.86

Peak ventilation
L min–1

40.93 ± 19.55

Metabolic equivalents
Ratio

3.65 ± 4.72

Peak heart rate
bpm

130.89 ± 31.06

VE-VCO2@AT

57.10 ± 23.22

NYHA = New York Heart Association, CPET = cardiopulmonary exercise testing,
RER = respiratory exchange ratio, Peak VO2 = peak oxygen consumption, VEVCO2@AT = minute ventilation-to-carbon dioxide output at anaerobic threshold,
CI: cardiac index.

CI. In our study, CI was the first variable that explained
the variance in 6MWT distance, indicating that lower CI
was associated with shorter 6MWT distance or functional
capacity. In addition, PAH patients in our study had a

higher CI (over 2.5 L min–1 m–2) with a mean value of 3.13
L min–1 m–2. Age was the second variable that explained
the variance in 6MWT distance in our study, indicating
that older age was associated with shorter 6MWT
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Table 2. Correlation r matrix of independent variables and 6-min walk test.
6MWT
Age (years)
Cardiac index (L min–1 –2)
Metabolic equivalents
VE-VCO2@AT
Peak VO2 (mL kg–1 min –1)
Peak work rate (W)

Age

r = 0.56**
P = 0.002
r = 0.27
P = 0.186
r = 0.74**
P = 0.001
r = 0.13
P = 0.634
r = 0.75**
P = 0.001
r = 0.57**
P = 0.002

CI

MET

VE-VCO2@AT

VO2peak

r = –0.08
P = 0.683
r = 0.56**
P = 0.002
r = –0.14
P = 0.827
r = 0.56**
P = 0.002
r = 0.69**
P = 0.001

r = 0.62**
P = 0.038
r = 0.29
P = 0.588
r = 0.42**
P = 0.032
r = 0.19
P = 0.348

r = 0.14**
P = 0.050
r = 1.00**
P = 0.001
r = 0.62**
P = 0.001

r = 0.14
P = 0.052
r = 0.26
P = 0.291

r = 0.62**
P = 0.001

Cardiac index = CI, Metabolic equivalent = MET, VE-VCO2@AT = minute ventilation-to-carbon dioxide output at anaerobic threshold,
Peak VO2 = peak oxygen consumption, ** = statistically significant.
Table 3. Linear regression model. Variables in the model.
β

t

P-value

CI

0.382

2.198

0.041

Age

0.494

2.840

0.010

Table 4. Exercise values in PAH patients categorized according to severity of reduction in 6MWT and CPET aerobic
capacity.
n = 19 Moderate PAH,
NYHA class II

n = 10 Severe PAH,
NYHA class III

P-value

0.95 ± 0.98

1.00 ± 0.12

0.172

13.55 ± 4.57

10.10 ± 3.21*

0. 025*

122.21 ± 60.90

132.44 ± 64.69

0.498

38.47 ± 17.65

40.66 ± 17.92

0.562

3.87 ± 1.30

2.87 ± 0.91*

0.025*

136.68 ± 26.50

114.0 ± 34.27

0.129

51.64 ± 18.11
77.26 ± 26.41

65.50 ± 29.75
77.60 ± 24.60

0.154
0.059

CI, L min–1 m –2

3.21 ± 1.09

2.75 ± 1.24

0.329

PVR, mmHg L–1 min–1

5.70 ± 2.81

7.38 ± 2.79

0.200

6MWT, m

426.05 ± 95.40

356.75 ± 89.94*

0.041*

RER maximal anaerobic threshold
Ratio
Peak VO2
mL min–1 kg–1
Peak work rate
W
Peak ventilation
L min–1
Metabolic equivalents
Ratio
Peak heart rate
bpm
VE-VCO2@AT
Ratio
Systolic PAP, mmHg

*Each 6MWT and CPET parameter of all class II and class III PAH patients was significantly different between
the groups (P < 0.05). Systolic PAP = Systolic pulmonary arterial pressure, Cardiac index = CI, PVR = pulmonary
vascular resistance, 6MWT= 6-min walk test.
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distance. These results are consistent with those of Enright
et al., who demonstrated that 6MWT distance is strongly
associated with age and that elderly subjects had lower
walking distances (18).
In the present study, we first demonstrated that the
distance walked in 6 min decreased in proportion to the
decrease in peak VO2 and MET determined by maximal
CPET. Maximal CPET results showed that patients with
PAH had reduced peak VO2 values. Peak VO2 assesses the
subject’s maximal work ability and maximal ability of the
circulatory system to increase CO. In PAH, this relates
to pulmonary vasculopathy, which limits blood flow
through the lungs (7). On the other hand, 6MWT distance
correlated modestly with VO2peak, MET, and workload in
the present study.
Additionally, considering the increased demand of
ventilatory deficiency, the minute ventilation-to-carbon
dioxide output slope increased in our PAH patients.
Previously, it was shown that 6MWT distance was
negatively correlated with VE-VCO2 slope in patients
with PAH (7). However, our findings did not show a
similar correlation. Only the hemodynamic parameter of
CI showed a statistically significant correlation with peak
VO2. This result shows that decreased CI causes reduced
oxygen consumption or functional capacity (21).

Several authors reported a close association between
6MWT distance and maximal exercise testing in patients
with heart failure, heart transplantation, and primary
pulmonary hypertension (7,22). Our analysis showed that
there were significant differences between the NYHA class
II and class III patients in terms of 6MWT distance, peak
VO2, and MET. Reduction and association among these
variables reflect right ventricle dysfunction, reduced CI,
and oxygen deficit during exercise (9). Concerning the
prognostic value of the submaximal 6MWT, it may be
concluded that the 6MWT can be used as an equivalent to
the peak VO2 parameter of maximal exercise testing.
In conclusion, submaximal exercise testing can be used
safely and easily to assess decreased functional capacity in
patients with PAH. The 6MWT provides information that
may be a better index for the patient’s NYHA functional
class determination than maximal exercise testing. The
determination of walking distance by CI and age indicators
enables patient-specific assessment of prognosis and
disease severity.
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